Post

Ocugen completes dosing in second cohort of OCU410 geographic atrophy trial

Biotechnology company Ocugen has completed dosing in the second cohort of its Phase I/II ArMaDa clinical trial of modifier gene therapy …

ACTG begins trial of three immune-based therapy combinations for HIV cure

ACTG has launched A5374, a Phase I/IIa clinical trial to evaluate the safety, tolerability, and antiviral effect of a combination …

Inozyme to run Phase III trial of INZ-701 in paediatric ABCC6 deficiency

Inozyme Pharma is speaking to the US Food and Drug Administration (FDA) about running a Phase III trial of INZ-701 …

Nexsen lays out clinical plans for rapid Strep B test development

Nexsen Biotech plans to evaluate the sensitivity and specificity of its rapid point of care for Group B streptococci (GBS), …

FDA approves Phase III trial of GenFleet’s KRAS G12C inhibitor

The US Food and Drug Administration (FDA) has granted approval for GenFleet Therapeutics’ Phase III clinical trial of GFH925, a …